-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August...
Barchart Research What to Expect from SVRA Earnings SVRA Generated August 11, 2026 Current Price $5.57 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 5.06% Will Savara's Quarter Reveal Whether...
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026 MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in...
-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow ® ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June...
-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking...
-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 -- -- All Patients Receive Molgramostim During the OL Treatment Period;...